Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Seladelpar治疗原发性胆汁性胆管炎患者3个月的疗效和安全性：ENHANCE，一项3期随机、安慰剂对照研究
期刊:Hepatology
影响因子:15.8
doi:10.1097/HEP.0000000000000395
Hirschfield, Gideon M; Shiffman, Mitchell L; Gulamhusein, Aliya; Kowdley, Kris V; Vierling, John M; Levy, Cynthia; Kremer, Andreas E; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C; Bowlus, Christopher L; Lawitz, Eric J; Aspinall, Richard J; Pratt, Daniel S; Raikhelson, Karina; Gonzalez-Huezo, Maria S; Heneghan, Michael A; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L; Mayo, Marlyn J; Dalekos, George N; Drenth, Joost P H; Janczewska, Ewa; Leggett, Barbara A; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J; Forman, Lisa; Jones, David E J; Ryder, Stephen D; Swain, Mark G; Steinberg, Alexandra; Boudes, Pol F; Choi, Yun-Jung; McWherter, Charles A
